Abstract: The present invention relates to the cosmetic use of a Khaya senegalensis extract, obtained by aqueous extraction, for maintaining and/or increasing the expression of collagen XVIII in the skin and/or the mucosae and/or the scalp and/or the skin appendages, for maintaining and/or increasing the firmness and/or the elasticity of the skin and/or the mucosae and/or the scalp and/or for reducing the visibility of the skin's pores and/or making the skin smoother and/or for limiting and/or reducing perspiration and/or limiting and/or reducing loss of head hair and/or body hair and/or increasing the growth of head hair and/or body hair and/or reducing or limiting sebum production.

Abstract: The present invention relates to the cosmetic use by the topical route of a Tapirira guianensis extract, for stimulating the expression of perlecan and/or dystroglycan and/or VE-cadherin and/or claudin-5, in particular in the extracellular matrix and/or in the epithelial basement membrane, especially the dermoepidermal junction. It also relates to a cosmetic care method comprising the application, to at least one concerned area of healthy skin and/or healthy mucous membrane and/or healthy scalp, of a Tapirire guianensis extract or of a cosmetic composition comprising such an extract for stimulating the expression of perlecan and/or dystroglycan and/or VE-cadherin and/or claudin-5, in particular in the extracellular matrix and/or in the epithelial basement membrane, especially the dermoepidermal junction. In addition, it relates to a cosmetic composition comprising a Tapirira guianensis extract and a topically acceptable cosmetic excipient.

Abstract: The present invention relates to the topical cosmetic use of a Polygonum bistorta extract for stimulating the expression of perlecan and/or dystroglycan, in particular in the extracellular matrix and/or in the epithelial basement membrane, especially the dermoepidermal junction. It also relates to a cosmetic care method comprising the application, to at least one concerned area of healthy skin and/or healthy mucous membrane and/or healthy scalp, of a Polygonum bistorta extract or of a cosmetic composition comprising such an extract for stimulating the expression of perlecan and of dystroglycan, in particular in the extracellular matrix and/or in the epithelial basement membrane, especially the dermoepidermal junction.

Abstract: A peptide is provided with a defined sequence present in the alpha3 chain of the LG4 globule of laminin 332 (laminin 5), and peptides with sequences homologous to the peptide with the defined sequence capable of binding to the syndecan-1 receptor. Pharmaceutical or cosmetic compositions containing the peptide are provided. The peptide is used in the area of tissue healing and regeneration or as an adjuvant in culture media intended for epidermal or epithelial reconstruction. The synthetic peptide comprises the sequence KKLRIKSKEK (SEQ ID NO: 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.

Abstract: The present invention relates to a monoclonal antibody binding to the LG4/5 domain of chain alpha3 of human protein laminin-5, wherein said monoclonal antibody inhibits the binding of syndecan-1 to said laminin-5 alpha3 chain LG4/5 domain, in particular 1H12 monoclonal antibody produced by the hybridoma cell line named 1H12 deposited on Jan. 8, 2008 at the C. N. C. M. under number 1-3890, as well as chimerized, humanized derivatives and fragments thereof, and nucleic acid sequences encoding them, as well as vectors and host cells expressing them. The invention further relates to the medical application of such antibodies, in particular for treating cancer.

Abstract: Synthetic peptide including the sequence KKLRIKSKEK (SEQ ID 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor.

Abstract: The present invention relates to a monoclonal antibody binding to the LG4/5 domain of chain alpha3 of human protein laminin-5, wherein said monoclonal antibody inhibits the binding of syndecan-1 to said laminin-5 alpha3 chain LG4/5 domain, in particular 1H12 monoclonal antibody produced by the hybridoma cell line named 1H12 deposited on Jan. 8, 2008 at the C. N. C. M. under number 1-3890, as well as chimerized, humanized derivatives and fragments thereof, and nucleic acid sequences encoding them, as well as vectors and host cells expressing them. The invention further relates to the medical application of such antibodies, in particular for treating cancer.

Abstract: Peptide of sequence TALRIRATYGEY (SEQ ID NO: 1) present on the gamma 2 chain of Laminin 5, a pharmaceutical composition containing the peptide and to the use of the composition for treating various skin alterations. More particularly, the treatment of the alterations includes reinforcing the derma-epidermal junction and the cell-matrix and/or cell-cell adherence of epidermis and in promoting the repair of a cutaneous surface.

Abstract: The invention relates to a novel peptide, a pharmaceutical composition containing said peptide and to the use of said composition for treating various skin alternations. More particularly, the treatment of said alterations consists in reinforcing the derma-epidermal junction and the cell-matrix and/or cell-cell adherence of epidermis and in promoting the repair of a cutaneous surface.

Abstract: The isolated proteins kalinin and k-laminin are disclosed to provide adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes of human subepithelial skin, trachea, esophagus, cornea and amnion when such areas are probed with BM165 monoclonal antibody after localization. The protein has a molecular weight of approximately 410-495 kDa and exists in a cell-associated form (about 495 kDa) and two medium-associated forms (about 460 and 410 kDa, respectively). The BM165 epitope is located on the 165-kDa and 200 kDa subunits. Kalinin has a rotary-shadow image revealing an asymmetric rod 107-nm long having two globules at a first end and a single globule at an opposing end. The k-laminin adhesion molecule is an isolated heterotrimeric laminin variant that has a molecular weight of about 650 kDa and separates on western blots into first and second fragments that are similar to the B1 and B2 fragments of laminin.

Abstract: A purified protein kalinin is disclosed that provides adhesion between epidermal keratinocytes and the underlying dermis. Purified kalinin localizes to the anchoring filaments of basement membranes or human subepithelial skin, trachea, esophagus, cornea and amnion when such areas are probed with BM165 monoclonal antibody after localization. The protein has a molecular weight of approximately 400-460 kDa and exists in a cell-associated form (about 460 kDa) and two medium-associated forms (about 440 and 400 kDa, respectively). The cell-associated form comprises a 200-, a 155- and a 140-kDa subunit, all normally held together by disulflde bonds. The cell-associated form is subjected to extracellular processing to produce the two medium-associated forms, wherein, in the 440-kDa form, the 200-kDa subunit has been processed to a 165-kDa subunit and, in the 400-kDa form, the 155-kDa subunit has been processed to a 105-KDa subunit. The BM165 epitope is located on the 165-kDa subunit.